Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

NCT01891968 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Bortezomib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]